Allakos Inc. (NASDAQ:ALLK) Short Interest Update

Allakos Inc. (NASDAQ:ALLK) was the recipient of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,390,000 shares, a decrease of 18.7% from the October 31st total of 1,710,000 shares. Based on an average daily volume of 667,500 shares, the short-interest ratio is presently 2.1 days.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a “market outperform” rating and issued a $3.00 target price on shares of Allakos in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $1.67.

Allakos Price Performance

ALLK opened at $1.03 on Monday. The stock’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $0.93. The stock has a market cap of $92.02 million, a P/E ratio of -0.51 and a beta of 1.03. Allakos has a 1-year low of $0.54 and a 1-year high of $3.41.

Allakos (NASDAQ:ALLK) last announced its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. Research analysts expect that Allakos will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Allakos

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Allakos by 8.9% during the 3rd quarter. Geode Capital Management LLC now owns 988,171 shares of the company’s stock worth $646,000 after acquiring an additional 80,763 shares during the period. RBF Capital LLC increased its holdings in shares of Allakos by 45.9% during the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after buying an additional 160,529 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Allakos in the 3rd quarter worth $1,143,000. FMR LLC boosted its holdings in Allakos by 14.6% in the third quarter. FMR LLC now owns 5,370,247 shares of the company’s stock valued at $3,508,000 after acquiring an additional 685,623 shares during the last quarter. Finally, GSA Capital Partners LLP grew its position in Allakos by 11.9% during the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after acquiring an additional 84,750 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.